Research Paper Volume 16, Issue 9 pp 8000—8018
A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance
Figure 1. Expression pattern of LDHA in pan-cancer. (A) Summary of mRNA and protein expression. (B) The expression level of LDHA in tumor and normal tissues via TIMER 2.0. (C) LDHA expression status in different types of cancers from TCGA and GTEx data. (D) The expression of LDHA in different types of cancers (LIHC, LUAD, PAAD, TGCT, THCA) was analyzed according to pathological stage (stage I, stage II, stage III, and stage IV). (E) Differences in LDHA expression between normal, tumor, and metastatic tissues among BRCA, COAD, KIRC, LUAD, PAAD, and PRAD. (F) Based on the HPA (https://www.proteinatlas.org/) database, representative immunohistochemical staining of LDHA in normal and tumor tissues of different cancer types. The p < 0.05 was considered to be statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001.